Point of Care (POC) Lipid Diagnostics Market, By Application (Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease), By Instrument (Roche Cobas b 101, Abaxis Piccolo Xpress, Roche Reflotron, Alere Cholestech LDX, and others) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) Analysis, Share, Trends, Size, & Forecast From 2014 2025
REPORT HIGHLIGHT
The Point of Care Lipid Diagnostics market is estimated to represent a global market of USD 210.5 million by 2017 with growth rate of 3.3%.
Market Dynamics
Point of care lipid testing is the testing of lipid content in order to improve the risk of cardiovascular disorders. Growing geriatric population coupled with rising sedentary lifestyle and unhealthy food habits are anticipated to stimulate the market growth. According to the World Health Organization (WHO), global population between the age group, 65 years and above is projected to rise from 7% in 2000 to 16% in 2050. Aging heightens the risk of chronic diseases such as cardiovascular diseases and diabetes. Lipid testing is an important parameter for monitoring variety of chronic diseases including diabetes, asthma, arthritis and other cardiovascular diseases. Increasing prevalence of such diseases is also expected to drive the market growth significantly. As per the statistics released by the WHO, patients affected with diabetes has risen from 108 million (1980) to 422 million (2014). Similarly, the International Diabetes Federation stated that around 425 million patients have diabetes globally. Growing disease incidences is projected to boost the demand for accurate, speedy and user-friendly diagnostic method, hence, driving the market growth.
Global POC Lipid Diagnostics Market by Application, 2017 vs 2025
Application Takeaway
The global Point of Care Lipid testing market is segmented into three levels: applications, instruments, and geography. Application segment is categorized as hyperlipidemia, hypertriglyceridemia, familial hypercholesterolemia, hyperlipoproteinemia, Tangier disease, and others. Hyperlipidemia segment has captured the large share of the total market. As per the Centres for Disease Control and Prevention, more than 78 million people suffer from abnormal cholesterol level in 2012 which is expected to increase in future years. Such facts will boost the use of point of care lipid diagnosis, leading to augment the market growth to great extent. On another hand, hypertriglyceridemia is projected to gain significant market share over the forecast period owing to the development of novel products. The instrument segment is divided into Roche Cobas b 101, Abaxis Piccolo Xpress, Roche Reflotron, Alere Cholestech LDX, Alere Afinion, Samsung LABGEO PT10, and Cardiocheck.
Regional Takeaway
Regionally, the market is categorized as North America, Europe, Asia Pacific and Rest of the World. Advancement in technologies such as the introduction of miniaturized diagnostic devices that renders rapid and accurate results such as CardioCheck Plus are anticipated to drive market growth in developed regions. Furthermore, rising demand for rapid, accurate, and sensitive diagnostic devices coupled with increasing prevalence of chronic diseases boost the market growth to some extent in these regions. Developing regions such as the Asia Pacific and Latin America is projected to grow with the significant growth rate over the forecast period owing to the increasing number of key players operating in this market and rising diabetes and cardiovascular incidences.
Key Vendor Takeaway
Samsung, Roche Diagnostics, Alere, Abaxis, Inc., and Bio-Rad Laboratories are profiled in the study. Extensive product portfolio and strategic collaborations with small-scale industry participants are considered to be the key strategies of these players. Other market leaders are also aggressively involved in new product development and expansion of distribution channels to capture a larger share of the market. Moreover, the companies are highly inclined toward maintaining competition in the market as well as delivering economic value to customers and satiate unmet demands.
The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.
The years considered for the study are:
- Historical Year – 2014 & 2015
- Base Year – 2015
- Estimated Year – 2016
- Projected Year – 2025
TARGET AUDIENCE
- Traders, Distributors, And Suppliers
- Manufacturers
- Hospitals
- Government and Regional Agencies and Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY APPLICATION
- Hyperlipidemia
- Hypertriglyceridemia
- Familial hypercholesterolemia
- Hyperlipoproteinemia
- Tangier disease
- Others
MARKET, BY INSTRUMENT
- Roche Cobas b 101
- Abaxis Piccolo Xpress
- Roche Reflotron
- Alere Cholestech LDX
- Alere Afinion
- Samsung LABGEO PT10
- Cardiocheck
MARKET, BY REGION
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- Rest of Europe
- Asia Pacific
- India
- China
- Rest of APAC
- Rest of the World
- Middle East and Africa
- Latin America
TABLE OF CONTENT
1. POC LIPID DIAGNOSTICS MARKET OVERVIEW
1.1. Study Scope
1.2. Base Year
1.3. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. POC LIPID DIAGNOSTICS KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. POC LIPID DIAGNOSTICS INDUSTRY STUDY
4.1. Porter’s Analysis
4.2. Regulatory Framework Analysis
4.3. Market Attractiveness Analysis
4.4. Value Chain Analysis
5. POC LIPID DIAGNOSTICS MARKET LANDSCAPE
5.1. Market Share Analysis
6. POC LIPID DIAGNOSTICS MARKET – BY APPLICATION:
6.1. Overview
6.2. Hyperlipidemia
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.3. Hypertriglyceridemia
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.4. Familial hypercholesterolemia
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.5. Hyperlipoproteinemia
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.6. Tangier disease
6.6.1. Overview
6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.7. Others
6.7.1. Overview
6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7. POC LIPID DIAGNOSTICS MARKET – BY INSTRUMENT:
7.1. Overview
7.2. Roche Cobas b 101
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.3. Abaxis Piccolo Xpress
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.4. Roche Reflotron
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.5. Alere Cholestech LDX
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.6. Alere Afinion
7.6.1. Overview
7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.7. Samsung LABGEO PT10
7.7.1. Overview
7.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.8. Cardiocheck
7.8.1. Overview
7.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8. POC LIPID DIAGNOSTICS MARKET– BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.2.3. U.S.
8.2.3.1. Overview
8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.2.4. Canada
8.2.4.1. Overview
8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3. Europe
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3.3. France
8.3.3.1. Overview
8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3.4. Germany
8.3.4.1. Overview
8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3.5. Rest of Europe
8.3.5.1. Overview
8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4. Asia Pacific (APAC)
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4.3. China
8.4.3.1. Overview
8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4.4. India
8.4.4.1. Overview
8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4.5. Rest of APAC
8.4.5.1. Overview
8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.5. Rest of the World
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.5.3. Latin America
8.5.3.1. Overview
8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.5.4. Middle East and Africa
8.5.4.1. Overview
8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9. KEY VENDOR ANALYSIS
9.1. Samsung
9.1.1. Company Overview
9.1.2. SWOT Analysis
9.1.3. Key Developments
9.2. Roche Diagnostics
9.2.1. Company Overview
9.2.2. SWOT Analysis
9.2.3. Key Developments
9.3. Alere
9.3.1. Company Overview
9.3.2. SWOT Analysis
9.3.3. Key Developments
9.4. Abaxis, Inc.
9.4.1. Company Overview
9.4.2. SWOT Analysis
9.4.3. Key Developments
9.5. Bio-Rad Laboratories
9.5.1. Company Overview
9.5.2. SWOT Analysis
9.5.3. Key Developments
*Client can request additional company profiling as per specific requirements
10. 360 DEGREE ANALYSTVIEW
11. APPENDIX
11.1. Research Methodology
11.2. Abbreviations
11.3. Disclaimer
11.4. Contact Us
List of Tables
Table 1 List of Acronyms
Table 2 Key Market Facts, 2014 – 2025
Table 3 Market Drivers: Impact Analysis
Table 4 Market Restraint: Impact Analysis
Table 5 Market Opportunity: Impact Analysis
Table 6 PEST Analysis
Table 7 Porter’s Five Forces Analysis
Table 8 Company Market Share Analysis
Table 9 Global POC Lipid Diagnostics Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
Table 10 POC Lipid Diagnostics Market, by Application, 2014 – 2025 (USD Million)
Table 11 POC Lipid Diagnostics Market, by Instruments, 2014 – 2025 (USD Million)
Table 12 POC Lipid Diagnostics Market, by Geography, 2014 – 2025 (USD Million)
Table 13 North America POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 14 U.S. POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 15 Canada POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 16 Europe POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 17 France POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 18 Germany POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 19 Asia Pacific POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 20 China POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 21 India POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 22 Latin America POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
Table 23 MEA POC Lipid Diagnostics Market, 2014 – 2025 (USD Million)
List of Figures
Figure 1 Research Methdology
Figure 2 Research Process Flow Chart
Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
Figure 4 Regulatory Framework Analysis
Figure 5 Value Chain Analysis Analysis
Figure 6 POC Lipid Diagnostics Market, by Application, 2014 – 2025 (USD Million)
Figure 7 POC Lipid Diagnostics Market, by Instrument, 2014 – 2025 (USD Million)
Figure 8 POC Lipid Diagnostics Market, by Geography, 2014 – 2025 (USD Million)
